An open-label tolerability study of BL-1020 antipsychotic: A novel gamma aminobutyric acid ester of perphenazine

Clinical Neuropharmacology

Volumn 33, Issue 6, 2010, Pages 297-302

  Anand, Ravi ^a   Geffen, Yona ^b   Vasile, Daniel ^c   Dan, Irina ^d  

^a APC AG   (Switzerland)

^b BIOLINERX LTD   (Israel)

^c CENTRAL MILITARY HOSPITAL   (Czech Republic)

^d Al Obregia Clinical Hospital   (Romania)

Author keywords

antipsychotic; extrapyramidal symptoms; GABA; schizophrenia

Indexed keywords

AMBAZONE; AMISULPRIDE; ANTIDEPRESSANT AGENT; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BL 1020; CARBAMAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; DIPYRONE; GLUCOSE; HALOPERIDOL; LEVOMEPROMAZINE; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PARACETAMOL; PYRIDOXINE; QUETIAPINE; RISPERIDONE; THIAMINE; THIOXANTHENE DERIVATIVE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOLPIDEM;

ADULT; AKATHISIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYNDROME; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERACTIVITY; HYPERPROLACTINEMIA; INSOMNIA; LABORATORY TEST; MALE; MULTICENTER STUDY; NAUSEA; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RESTLESSNESS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; SUICIDAL IDEATION; TREMOR;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, INVESTIGATIONAL; DYSTONIA; FEMALE; GABA-A RECEPTOR AGONISTS; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; PERPHENAZINE; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SLEEP INITIATION AND MAINTENANCE DISORDERS; YOUNG ADULT;

EID: 78650286078     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181f8d501     Document Type: Article

References (23)

1. AbidiS, Bhaskara SM. From chlorpromazine to clozapineVantipsychotic adverse effects and the clinician's dilemma. Can J Psychiatry 2003;48:749-755.
2. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696.
3. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371.
4. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-296.
5. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566.
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223.
7. Nudelman A, Gil-Ad I, Shpaisman N, et al. A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects. J Med Chem 2008;51:2858-2862.
8. Geffen Y, Nudelman A, Gil-Ad I, et al. BL-1020: A novel anti-psychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. Eur Neuropsychopharmacol 2009;19:1-13.
9. Akbarian S, Huntsman MM, Kim JJ, et al. GABAA receptor subunit gene expression in human prefrontal cortex: comparison of schizophrenics and controls. Cereb Cortex 1995;5:550-560.
10. Beasley CL, Reynolds GP. Parvalbumin-immunoreactive neurons are reduced in the prefrontal cortex of schizophrenics. Schizophr Res 1997;24:349-355.
11. Benes FM. Emerging principles of altered neural circuitry in schizophrenia. Brain Res Brain Res Rev 2000;31:251-269.
12. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999;122(Pt 4):593-624.
13. Simpson MD, Slater P, Deakin JF, et al. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci Lett 1989;107: 211-215.
14. Wassef A, Baker J, Kochan LD. GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychopharmacol 2003;23:601-640.
15. Lloyd KG. The neuropathology of GABA neurons in extrapyramidal disorders. J Neural Transm 1980;16:217-227.
16. Guidotti A, Auta J, Davis JM, et al. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacology (Berl) 2005;180:191-205.
17. Appel L, Geffen Y, Heurling K, et al. BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans. Eur Neuropsychopharmacol 2009;19:841-850.
18. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276.
19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised Edition. Rockville, MD: National Institute of Mental Health: US Department of Health Education and Welfare; 1976.
20. FDA. Good Clinical Practice in FDA-Regulated Clinical Trials2005: Available from: http://www.fda.gov/oc/gcp/default.htm. Accessed June 16, 2010.
21. Potkin SG, Gharabawi GM, Greenspan AJ, et al. Psychometric evaluation of the Readiness for Discharge Questionnaire. Schizophr Res 2005;80:203-212.
22. Chouinard G, Margolese H. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res 2005;76:247-265.
23. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233-239.